These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 19549574)

  • 1. Advances in antibacterial therapy against emerging bacterial pathogens.
    Pournaras S; Iosifidis E; Roilides E
    Semin Hematol; 2009 Jul; 46(3):198-211. PubMed ID: 19549574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for multidrug-resistant bacteria.
    Giamarellou H
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):601-18. PubMed ID: 17009940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The current state of multidrug-resistant gram-negative bacilli in North America.
    Nicasio AM; Kuti JL; Nicolau DP
    Pharmacotherapy; 2008 Feb; 28(2):235-49. PubMed ID: 18225969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE; Rybak MJ
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
    Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
    J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment.
    McDonald LC
    Clin Infect Dis; 2006 Jan; 42 Suppl 2():S65-71. PubMed ID: 16355319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia.
    Ferrara AM
    Int J Antimicrob Agents; 2006 Mar; 27(3):183-95. PubMed ID: 16472990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Has the era of untreatable infections arrived?
    Livermore DM
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i29-36. PubMed ID: 19675016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of serious nosocomial bacterial infections: do current therapeutic options meet the need?
    Lode H
    Clin Microbiol Infect; 2005 Oct; 11(10):778-87. PubMed ID: 16153251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum.
    McGowan JE
    Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S29-37; discussion S64-73. PubMed ID: 16813979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006.
    Zhanel GG; DeCorby M; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; Mulvey MR; Hoban DJ;
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):67-80. PubMed ID: 18513913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Important aspects of nosocomial bacterial resistance and its management.
    Kandelaki G; Tsertsvadze T; Macharashvili N; Esugbaia M; Gogichaishvili Sh
    Georgian Med News; 2008 Dec; (165):49-54. PubMed ID: 19124917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiologic spectrum and susceptibility pattern of clinical isolates from the pediatric intensive care unit in a single medical center - 6 years' experience.
    Lee CY; Chen PY; Huang FL; Lin CF
    J Microbiol Immunol Infect; 2009 Apr; 42(2):160-5. PubMed ID: 19597649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet medical needs in antibacterial therapy.
    Rice LB
    Biochem Pharmacol; 2006 Mar; 71(7):991-5. PubMed ID: 16280121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapeutic options for the treatment of multiresistant bacteria in the ICU].
    Barcenilla Gaite F; Jover Saenz A; Vallverdú Vidal M; Castellana Perello D
    Rev Esp Quimioter; 2008; 21 Spec No 1():9-13. PubMed ID: 18752075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antibiotics: optimal use in current clinical practice.
    Karageorgopoulos DE; Falagas ME
    Int J Antimicrob Agents; 2009; 34 Suppl 4():S55-62. PubMed ID: 19931821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective digestive tract decontamination--will it prevent infection with multidrug-resistant gram-negative pathogens but still be applicable in institutions where methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci are endemic?
    Bonten MJ
    Clin Infect Dis; 2006 Sep; 43 Suppl 2():S70-4. PubMed ID: 16894518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant pathogen-associated skin and skin-structure infections: antibiotic options.
    Curcio D
    Expert Rev Anti Infect Ther; 2010 Sep; 8(9):1019-36. PubMed ID: 20818946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metallo-beta-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?
    Maltezou HC
    Int J Antimicrob Agents; 2009 May; 33(5):405.e1-7. PubMed ID: 19095416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New antibiotic agents for bloodstream infections.
    Vergidis PI; Falagas ME
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S60-5. PubMed ID: 18723329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.